Liberum Capital reiterated their buy rating on shares of AstraZeneca plc (LON:AZN) in a research report report published on Monday. Liberum Capital currently has a GBX 4,800 ($61.99) target price on the biopharmaceutical company’s stock.

A number of other research analysts have also commented on the company. J P Morgan Chase & Co reissued a neutral rating and set a GBX 4,200 ($54.24) price objective on shares of AstraZeneca plc in a report on Friday, September 8th. Citigroup Inc. reissued a buy rating on shares of AstraZeneca plc in a report on Thursday, September 7th. Natixis raised AstraZeneca plc from a neutral rating to a buy rating and increased their price objective for the company from GBX 5,000 ($64.57) to GBX 5,738 ($74.11) in a report on Wednesday, September 6th. Deutsche Bank AG reissued a buy rating and set a GBX 5,300 ($68.45) price objective on shares of AstraZeneca plc in a report on Tuesday, September 5th. Finally, UBS AG set a GBX 4,550 ($58.76) price objective on AstraZeneca plc and gave the company a neutral rating in a report on Thursday, August 31st. Three analysts have rated the stock with a sell rating, ten have given a hold rating and nine have issued a buy rating to the company’s stock. The stock has an average rating of Hold and an average target price of GBX 5,022.91 ($64.87).

AstraZeneca plc (LON:AZN) opened at 4866.00 on Monday. The stock’s market capitalization is GBX 61.60 billion. The firm has a 50-day moving average of GBX 4,560.14 and a 200 day moving average of GBX 4,882.27. AstraZeneca plc has a 52 week low of GBX 3,996.00 and a 52 week high of GBX 5,520.00.

TRADEMARK VIOLATION NOTICE: “AstraZeneca plc’s (AZN) “Buy” Rating Reiterated at Liberum Capital” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/09/14/astrazeneca-plcs-azn-buy-rating-reiterated-at-liberum-capital.html.

The business also recently announced a dividend, which was paid on Monday, September 11th. Investors of record on Thursday, August 10th were given a dividend of GBX 68.90 ($0.89) per share. The ex-dividend date of this dividend was Thursday, August 10th. This represents a dividend yield of 1.35%.

In other AstraZeneca plc news, insider Nazneen Rahman purchased 39 shares of the company’s stock in a transaction that occurred on Thursday, July 27th. The stock was purchased at an average cost of GBX 4,370 ($56.44) per share, with a total value of £1,704.30 ($2,201.08).

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.